Overview

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

Status:
RECRUITING
Trial end date:
2029-05-01
Target enrollment:
Participant gender:
Summary
A single-center phase Ib/II dose escalation and dose-expansion clinical trial of REGN5678 plus cemiplimab
Phase:
PHASE1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Regeneron Pharmaceuticals
Treatments:
cemiplimab